SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing significant volatility and community buzz driven by its low circulating supply, leading to active speculation about potential short squeezes and large price expansions. Investors are closely tracking its performance alongside broader Solana ecosystem trends, with many debating entry points and speculating on future growth targets.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of the preliminary design for its Phase 3 trial of CAD-1005 for treating heparin-induced thrombocytopenia. While the community is discussing the potential registration path and upcoming clinical milestones, sentiment is polarized, with some investors optimistic about the pipeline progress while others express significant skepticism regarding the company's long-term financial stability and frequent use of stock offerings.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

Mullen's crypto token is trending as the community debates its origins and ties to the history of the Mullen Automotive stock, which faced significant controversy regarding dilutions and reverse splits. Investors are divided, with some promoting the token as a high-potential speculative play while many others dismiss it as a pump-and-dump scheme linked to previous corporate scandals.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is seeing intense activity driven by a low-float, speculative AI-narrative, with traders actively monitoring its technical structure for potential squeeze setups. Community discussion centers on high volatility and the stock's sensitivity to momentum-based trading, as investors weigh the risks of dilution against the possibility of significant upside volatility.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

DOGI is gaining momentum as a leading DRC-20 token on the Dogecoin network, with community members emphasizing its connection to the Doginals ecosystem and upcoming platform utility. Investors are actively discussing the token's potential growth alongside other BRC-20 assets, citing increased transaction activity and the broader expansion of the memecoin sector as key drivers.

Envela Corp. engages in recycling and re-commerce services at the forefront of the circular economy. It operates through the following segments: Consumer and Commercial. The Consumer segment focuses on selling authenticated high-end luxury goods, including pre-owned and repurposed fine jewelry, diamonds, gemstones, luxury watches, and secondary market bullion. The Commercial segment provides solutions for de-manufacturing end-of-life electronic assets, reclaiming base and precious metals, and other saleable materials. The company was founded on September 16, 1965 and is headquartered in Irving, TX.

Envela Corp

Envela Corp is seeing increased community interest driven by its strategic expansion into the circular economy and robust performance in IT asset disposition services. Traders are highlighting the stock's strong relative strength and volume as it builds momentum, while noting its profile as a potential growth play within the small-cap sector.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing community attention as a key infrastructure project in the Base ecosystem, with investors closely watching its AI agent capabilities and ongoing platform developments. Traders are actively debating the coin's utility-driven long-term potential versus short-term volatility, while many remain focused on accumulation strategies during current market movements.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is currently facing significant market attention following an earnings report that featured a revenue miss, prompting intense debate among retail traders regarding its valuation and long-term profitability. While some investors remain optimistic about the company's expansion into new verticals and its aggressive growth strategy, community discussions are heavily polarized by concerns over intensifying competition, shifting consumer spending habits, and regulatory scrutiny surrounding gig economy labor practices.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is experiencing intense community speculation and bullish sentiment as traders anticipate potential listings on major U.S. exchanges and look for the coin to repeat the zero-dropping performance of other successful meme coins. Investors are actively debating the impact of upcoming exchange integration, supply burn mechanisms, and historical price patterns, fueling a high-energy environment for long-term holders.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is trending following a massive tax refund from the IRS that significantly boosted its cash liquidity, sparking active community discussion regarding a potential short squeeze given the stock's elevated short interest. Investors are closely debating the company's valuation against this new capital infusion while monitoring for further catalysts like potential CHIPS Act funding and growth in the AI data center sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Investor focus shifted toward a shareholder vote on a proposal to expand the company’s incentive share pool by 20 million shares.</li><li>CEO Angelos Stergiou urged investors to support the expansion, reiterating confidence in the Phase 3 Regal trial.</li><li>The Regal study had recorded 72 overall-survival events as of Dec. 26, nearing the 80-event threshold required to trigger topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) hovered near the $5 level on Thursday as investor attention shifted from upcoming AML trial results to a shareholder vote on a proposal to add 20 million shares to the company’s incentive plan.SLS stock jumped 6% on Thursday to end at 4.95, climbing close to the $5 threshold last hit more than a month ago.&nbsp;<h2 class="st-heading-2">Sellas Seeks 20M Share Incentive Expansion</h2>Sellas CEO Angelos Stergiou recently urged shareholders to support a proposal to expand the share reserve under the company’s 2023 Amended and Restated Equity Incentive Plan by 20 million shares, saying his conviction in the Phase 3 Regal study evaluating GPS in acute myeloid leukemia (AML) remains unchanged.Sellas previously disclosed that 72 overall-survival events had been recorded as of Dec. 26, moving the study closer to the 80-event threshold required for topline analysis. Stergiou also said that a slower accumulation of survival events in oncology trials can sometimes indicate that patients are living longer than initially expected.The proposed equity plan would replenish the company’s stock-based compensation pool after Sellas said only 7,991 shares remained available for future awards under the existing plan as of mid-April. Approval would also allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect.As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.<h2 class="st-heading-2">Retail Flags Dilution Concerns Near $5</h2>Retail investors on Stocktwits voiced concerns about the timing and scale of the proposed equity plan, particularly as the Regal Phase 3 milestone approaches. Sentiment for SLS slipped to ‘neutral’ from ‘bullish’ levels a week ago amid a 32% rise in 24-hour message volumes.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_a286a7daf7.webp" alt="sls ss.png" width="966" height="146"><figcaption>SLS sentiment and message volume as of May 1 | Source: Stocktwits</figcaption></figure>Some investors&nbsp;<a href="https://stocktwits.com/nashvilleRN/message/651903417">argued</a> that the proposal represented about a 20% dilution, questioning whether such a request should be made before the full Phase 3 data are revealed. Meanwhile, another turned&nbsp;<a href="https://stocktwits.com/Usser888990/message/651903766">bearish</a> at the idea of diluting the stock around the $5 range.&nbsp;In a separate&nbsp;<a href="https://stocktwits.com/FlockOfSeagulls/message/651841400">investor poll</a>, about 70% of respondents indicated they planned to vote against the proposal, compared with 30% supporting it. Another investor&nbsp;<a href="https://stocktwits.com/Bio_Wizard/message/651898473">said</a> that they had already voted against the measure and rotated capital into long-term equities.&nbsp;<h2 class="st-heading-2">AML Pipeline Remains In Focus</h2>Despite the debate regarding share dilution, investors are closely watching the upcoming milestones from the company’s AML programs. The event-driven Phase 3 Regal study is evaluating GPS, which activates immune cells that help destroy leukemia cells in patients whose AML returned but later entered remission after additional therapy.Stergiou also pointed to 2026 as an important year for the company’s CDK9 inhibitor SLS009, with clinical updates and top-line data expected from ongoing Phase 2 studies.Preclinical findings presented ahead of a recent cancer summit showed that the therapy triggered the natural self-destruction process in leukemia cells, reduced survival-support proteins, and remained active in AML linked to ASXL1 and TP53 mutations, which are typically associated with poorer outcomes.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-amazon-drives-auto-revenue-r2-buzz/cZQNMpZReIN">Rivian Stock Slides Overnight: Investors Look Past R2 Buzz To Amazon’s Growing Grip On Auto Revenue&nbsp;</a>

SLS stock jumped 6% on Thursday to end at 4.95. (Photo credit: Getty Images)

SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results 

Sellas reported 2.64 million stock options and 2.26 million RSUs outstanding as of April 15, representing an equity overhang of about 2.6% of the total float.

Equity

<ul class="summary-bullets"><li>Markets eased from record highs as investors brace for the Fed rate decision and a crucial wave of Big Tech earnings.&nbsp;</li><li>Brent oil prices surged above $110 amid renewed geopolitical tensions in the Middle East.</li><li>Gold slips to a three-week low, signaling mixed safe-haven positioning.</li></ul>U.S. stock futures retreated from record highs early Tuesday as investors tread carefully ahead of big tech earnings and the Fed's rate decision tomorrow. Geopolitical tensions are also weighing on sentiment. Hopes for a swift resolution to the conflict in the Middle East dimmed after President Trump reportedly expressed skepticism over Iran’s latest peace proposal.Brent crude soared above $110, while gold slipped to a three-week low. As of 4:00 a.m. ET on Tuesday: Nasdaq futures declined 0.5%, S&amp;P 500 futures slipped 0.3%, Russell 2000 futures were down 0.1%, while Dow futures were flat.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, has moved back to ‘bullish’ territory, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bearish’, as the tech sector heads into a critical earnings stretch.&nbsp;Trending Stocks To WatchPoet Technologies (POET):&nbsp;Shares were down another 9% in early pre-market trade on news that&nbsp;Marvell Technologies (MRVL) canceled a purchase order connected to its Celestial AI unit.&nbsp;Sellas Lifesciences (SLS):&nbsp;A portfolio manager, Commonwealth Equity Services, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.Nvidia (NVDA) has solidified its status as the most valuable company in the world after hitting a new 52-week high on AI-driven momentum in Monday’s session.&nbsp;Google (GOOGL) has reportedly joined OpenAI and xAI in signing a deal with the U.S. Department of Defense to allow its AI models to be used for classified military work.&nbsp;Oracle (ORCL)&nbsp;is attracting retail interest, driven by buzz around OpenAI's financial health and Oracle’s role as its primary AI backbone.&nbsp;Bed Bath &amp; Beyond (BBBY)&nbsp;is trending on retail radar after reporting its first quarterly revenue growth in five years.&nbsp;Joby Aviation (JOBY):&nbsp;A successful air-taxi demo and a confirmed target for passenger flights in late 2026 are driving this stock 3% higher in early premarket trading.&nbsp;Dynatrace (DT):&nbsp;Activist investor Starboard Value has reportedly built a significant stake in the AI software maker.&nbsp;Intellia Therapeutics (NTLA) and Rocket Labs (RKLB): Cathie Wood’s ARK Invest sold off a portion of its position in Rocket Labs, while adding on to Intellia Therapeutics.&nbsp;Other tickers trending on Stocktwits&nbsp;at the time of writing included Moolec Science SA (MLEC), Canadian Solar Inc (CSIQ), Vir Biotechnology (VIR), and Nio Inc (NIO).Other Catalysts To WatchOn the economic front, traders will be watching the release of the JOLTS Job Openings and CB Consumer Confidence reports this morning.On earnings radar, watch out for quarterly reports from&nbsp;UPS (UPS), General Motors (GM), Commvault Systems (CVLT), JetBlue (JBLU), Sysco (SYY), Spotify (SPOT), Coca-Cola (KO), T-Mobile (TMUS), Kimberly Clark (KMB), Centene (CNC), and Zimmer Biomet (ZBH), before the bell. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Before Fed Call, Earnings Rush: Why POET, MRVL, NVDA, ORCL, SLS Are In Focus

Data from Stocktwits show mixed positioning, with retail turning bullish on SPY but remaining cautious on QQQ.

<ul class="summary-bullets"><li>Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares worth $162,730.</li><li>CEO Angelos Stergiou reaffirmed confidence in the trial, saying his conviction in its commercial potential remains “as steadfast today as it was day 1.”</li><li>Sellas is also seeking shareholder approval to expand its equity incentive plan by 20 million shares.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) came into focus on early Tuesday after a portfolio manager, known for backing several “Magnificent Seven” stocks, increased its stake in the cancer drugmaker ahead of a survival-event trigger in its Phase 3 acute myeloid leukemia (AML) program.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> jumped over 9% on Monday amid rising hopes around the database-lock milestone for Sellas’ Regal study, which could unlock topline survival data from its lead immunotherapy candidate, GPS.<h2 class="st-heading-2">SLS Draws Fresh Institutional Interest</h2>On Monday, Commonwealth Equity Services increased its stake by 32%, adding 9,226 shares to bring its total holdings to 38,470 shares valued at about $162,730 as of March 31. The boost in stake places Sellas among its other heavyweight healthcare bets, including Eli Lilly, Pfizer, and UnitedHealth.Among its larger portfolio, Sellas sits among its “Magnificent Seven” allocations, including Apple, Nvidia, Microsoft and Amazon.Recently, BlackRock also disclosed ownership of 12.1 million shares, representing 6.8% of Sellas’ shares. Additionally, Dagco raised its position by 78% to 1.03 million shares valued at $4.35 million, making Sellas its second-largest allocation alongside healthcare holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.<h2 class="st-heading-2">CEO Reaffirms Confidence In Sellas’ AML Trial</h2>The increase in stake comes after Sellas CEO Angelos Stergiou said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-jumps-overnight-ceo-backs-aml-drug-20m-share-plan/cZBNIW8Re2E">late Sunday</a> that his confidence in the Regal study’s commercial potential remains unchanged despite the trial remaining blinded. “My conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1,” he said.The ongoing event-driven Phase 3 Regal study is evaluating GPS in patients whose acute myeloid leukemia returned but later entered remission following additional therapy. Final analysis is expected once 80 overall-survival events are recorded, which will trigger database lock, statistical analysis and unblinding. The company previously reported 72 survival events as of Dec. 26, bringing the study closer to the required threshold. Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than initially expected.Beyond the Regal program, Stergiou also said investors should expect updates and topline data readouts from ongoing Phase 2 studies of the company’s CDK9 inhibitor SLS009 this year.&nbsp;<h2 class="st-heading-2">Sellas Proposes 20M Share Reserve Increase&nbsp;</h2>Alongside pipeline progress, Sellas is seeking shareholder approval to expand its share reserve under its 2023 Amended and Restated Equity Incentive Plan by 20 million shares.The company said that only 7,991 shares are available for future awards under the existing plan as of mid-April. The approval would allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect. If rejected, the award would automatically be canceled, and alternative compensation arrangements may be required.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_656e44509c.webp" alt="sls ss.png" width="968" height="147"><figcaption>SLS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/OnTheBalance/message/651586857">said</a>, “Far more important than Blackrock or Vanguard is the fact that private wealth and family offices have been actively buying and hoarding shares. Lot of money in that segment. Careful but patient money.”<stembedurl>https://stocktwits.com/OnTheBalance/message/651586857</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Macme/message/651533145">said</a>, “The CEO must have already discussed this 20 million shares with huge partners. It wil pass. Retail is just making noise. The real players like blackrock will surely approve.”<stembedurl>https://stocktwits.com/Macme/message/651533145</stembedurl>SLS stock has surged nearly 250% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-400m-pay-retail-bullish-ahead-of-earnings/cZB8nCTRe5L">Rivian CEO Got $400M While EV Maker Lost $3.6B Last Year — Retail Is Bullish Anyway As Q1 Earnings Near&nbsp;</a>

SLS stock has surged nearly 250% over the past year. (Photo credit: Getty Images)

SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger 

Commonwealth holds Sellas alongside major healthcare names like Eli Lilly, Pfizer, and UnitedHealth.

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>The CEO reaffirmed confidence in the Phase 3 Regal trial evaluating GPS in AML, despite the study remaining blinded.</li><li>Sellas expects clinical updates and Phase 2 readouts for its CDK9 inhibitor, SLS009, this year.</li><li>BlackRock disclosed a 6.8% stake in the cancer drugmaker on Friday.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped over 7% overnight late Sunday after its CEO signaled “steadfast” confidence in the company’s lead acute myeloid leukemia (AML) therapy and urged investors to support a proposal to expand its equity incentive plan by 20 million shares.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> slid about 15% last week, logging its worst weekly performance in nearly four months.<h2 class="st-heading-2">Sellas CEO Signals ‘Steadfast’ Confidence In Regal Trial</h2>CEO Angelos Stergiou said in a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7454295346865729537/">LinkedIn post</a> late Sunday that his conviction in the Regal trial’s commercial prospects remains unchanged despite the study still being blinded.“My conviction in the REGAL trial’s prospects and ultimate commercial potential remains as steadfast today as it was day 1,” he said. The ongoing event-driven Phase 3 Regal study is evaluating GPS in patients whose AML returned but later entered remission after additional therapy. Final analysis of the trial is expected once 80 overall-survival events are recorded, which triggers database lock, statistical analysis and unblinding.Sellas previously said 72 survival events had been recorded as of Dec. 26, bringing the study closer to the milestone required for topline analysis. Stergiou also said that slower accumulation of survival events in cancer studies can sometimes indicate that patients are living longer than initially expected.“While strict trial blinding prevents any definitive guarantees before unblinding, my belief in the asset—and the prolonged survival trend we are observing—has not diminished in the slightest,” Stergious said in the post.GPS targets Wilms Tumor-1 (WT1), a protein commonly found in many cancers and ranked by the National Cancer Institute as a leading immunotherapy target. The treatment uses engineered fragments of WT1 to activate key immune cells that help destroy cancer cells.<h2 class="st-heading-2">SLS009 Updates Expected This Year</h2>Stergiou also pointed to 2026 as an important year for&nbsp;the development of the CDK9 inhibitor SLS009. “Investors should look for clinical updates and top-line data readouts from our ongoing Phase 2 studies this calendar year,” he said.Recent lab findings presented ahead of a key cancer summit showed that the therapy helped trigger the natural self-destruction process in leukemia cells while reducing proteins that cancer cells rely on to survive. The drug also remained active in hard-to-treat forms of AML linked to ASXL1 and TP53 mutations, which are typically associated with poorer outcomes.Investor expectations had been building around potential updates from SLS009 last week, leaving the stock in&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-slips-after-hours-cancer-pipeline-silence-china-licensing-arbitration/cZBBanERI6u">wait-and-watch mode</a> after the anticipated pipeline developments did not immediately land at a cancer summit.<h2 class="st-heading-2">Sellas Seeks Approval To Add 20M Shares</h2>Alongside pipeline updates, Stergiou sought approval to expand the share reserve under its 2023 Amended and Restated Equity Incentive Plan by 20 million shares. The amendment would add more shares to the company’s stock-based compensation pool after Sellas disclosed that only 7,991 shares remained available for future awards under its existing plan as of mid-April.Approval of the new proposal would allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect, while rejection would automatically cancel the award and could require the company to consider alternative compensation arrangements.As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.&nbsp;<h2 class="st-heading-2">Institutional Participation Builds Ahead Of Catalysts</h2>Institutional participation in the stock has remained active ahead of expected clinical milestones. On Friday, BlackRock disclosed a stake of about 12.1 million shares, representing 6.8% of Sellas’ outstanding common stock.Data compiled by Quiver Quantitative showed last week that Dagco&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-premarket-dagco-raises-stake-ahead-of-aacr-leukemia-data/cZBIfhbRICL">increased its stake</a> by 78%, bringing its total holdings to 1.03 million shares valued at about $4.35 million as of March 31. The position now represents Dagco’s second-largest disclosed allocation at 1.01% of its portfolio, placing Sellas among its healthcare bets alongside larger pharma companies such as Merck, Thermo Fisher Scientific, and Johnson &amp; Johnson.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has jumped to ‘bullish’ from ‘bearish’ levels over the past week amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_9245b89031.webp" alt="sls ss.png" width="973" height="142"><figcaption>SLS sentiment and message volume as of April 26 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/vlucky16/message/651465697">said</a>, “Sterge doing what's best for patients and stockholders. Just sit back and watch warrants and loose shares get gobbled up. At some point Game Over for shorts!!!”<stembedurl>https://stocktwits.com/vlucky16/message/651465697</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/PejalPapa/message/651464553">said</a>, “I would at least like to see an IDMC report with event no and a signal to keep going. Not sure how his posts like that are building a shareholder value with so much uncertainty on the direction of the trial.”<stembedurl>https://stocktwits.com/PejalPapa/message/651464553</stembedurl>SLS stock has surged 233% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jpmorgan-sees-tokenized-etfs-as-the-next-big-thing/cZBkpZpRe23">JPMorgan Sees Tokenized ETFs As The Next Big Thing, But Adoption Timeline Is Still Unclear</a>

SLS stock has surged 233% over the past year. (Photo credit: Getty Images)

SLS Stock Jumps Overnight: CEO Doubles Down On ‘Steadfast’ Confidence In AML Drug And Pushes For 20M Share Plan Approval 

Sellas is seeking approval to add 20 million shares to its equity plan after nearly exhausting its current pool, with only 7,991 shares remaining.

SELLAS Life Sciences Group (NASDAQ:SLS)  Shares Down 8.1%   - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 8.1% - Here's Why...

<ul class="summary-bullets"><li>Anticipated updates on the company’s leukemia drug SLS009 did not land, dampening near-term catalyst momentum.</li><li>Earlier studies showed SLS009 triggered leukemia cell death and remained active in difficult-to-treat AML cases with ASXL1 and TP53 mutations.</li><li>Attention also remains on the Phase 3 Regal trial, where survival events are approaching the threshold required to begin topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) slipped nearly 1% in after-hours trading on Tuesday as investors remained in wait-and-watch mode after expected cancer-pipeline updates failed to land, turning focus toward a pending China licensing arbitration decision tied to Phase 3 milestone payments for its lead acute myeloid leukemia (AML) program.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> ended the regular session about 1% higher at $5.03.<h2 class="st-heading-2">SLS009 Update Fails To Land</h2>Investor expectations had been building around potential updates on the company’s leukemia drug SLS009, which earlier studies showed could help trigger cancer cell death while blocking survival signals that leukemia cells rely on. The treatment also showed activity in hard-to-treat AML cases with ASXL1 and TP53 mutations, genetic changes often linked to poorer outcomes.SLS shares also drew investor attention on Tuesday after U.S. investment manager Dagco&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-premarket-dagco-raises-stake-ahead-of-aacr-leukemia-data/cZBIfhbRICL">increased</a> its stake in the company by 78% ahead of anticipated catalysts in the company's leukemia pipeline.<h2 class="st-heading-2">China Milestone Payment Dispute In Focus</h2>Focus has now turned to an arbitration proceeding involving Sellas and its Chinese partner 3D Medicines covering development and commercialization rights for 3D189, the regional version of the company’s immunotherapy candidate Galinpepimut-S (GPS), as well as 3D059, the regional version of SLS009.The arbitration includes disputes over milestone payments tied to the initiation of Phase 3 clinical development for 3D189, and whether the regional partner maintained sufficient expertise and resources to meet its obligations under the licensing agreement.The tribunal directed both parties to submit final closing submissions by April 21, moving the case into its decision phase.&nbsp;Sellas previously said that it received $10.5 million in upfront and milestone payments under its Greater China agreement with 3D Medicines, while up to $191.5 million in additional development, regulatory and commercial milestone payments remain possible under the licensing deal, excluding potential future royalties.<h2 class="st-heading-2">Regal Trial Readout Watch Builds</h2>Beyond the arbitration process, investor attention continues to center on the company’s ongoing Phase 3 Regal trial evaluating GPS as a maintenance therapy for AML patients whose disease returned but later entered remission after additional therapy.Sellas previously said 72 overall survival events had been recorded as of late December, approaching the 80-event threshold required to begin topline analysis. CEO Angelos Stergiou has said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than expected compared with historical assumptions.However, with no meaningful update emerging from the summit session as expected, attention appears to shift toward another near-term catalyst for the drugmaker.&nbsp;<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS has improved to ‘bullish’ from ‘neutral’ levels a day ago amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_8e6702e3ff.webp" alt="sls ss.png" width="968" height="144"><figcaption>SLS sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/Arnold_Stonkinator/message/650962118">noted</a> that while the SLS009 poster presentation drew attention, the absence of a formal company update or management communication on National AML Awareness Day stood out.<stembedurl>https://stocktwits.com/Arnold_Stonkinator/message/650962118</stembedurl>Another user expressed frustration, saying, “If they are going to go silent then do that and don't go to conferences, don't tweet, stop communicating completely.&nbsp; It just gives Shorts something else to see. Sterg we don't want to hear from you unless it is a BO.”<stembedurl>https://stocktwits.com/StandingByWaiting/message/650959906</stembedurl>SLS stock has surged 290% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-pares-losses-after-hours-citi-amazon-glp1-caveat/cZBB74RRI6q">HIMS Stock Pares Losses After-Hours: Citi Flags ‘Big Caveat’ In Amazon’s GLP-1 Push That Limits Risk To Hims Model</a>

SLS stock has surged 290% over the past year.  (Photo credit: Getty Images)

SLS Stock Slips After-Hours As Cancer Pipeline Silence Frustrates Retail — China Licensing Fight Now In Spotlight

SLS Stock - Investor focus has shifted to an ongoing arbitration with 3D Medicines over Phase 3 milestone payments tied to the Greater China rights for GPS and SLS009.

Investor focus has shifted to an ongoing arbitration with 3D Medicines over Phase 3 milestone payments tied to the Greater China rights for GPS and SLS009.

<ul class="summary-bullets"><li>Dagco added 451,240 shares, making Sellas its second-largest holding at 1.01% of portfolio weight.</li><li>The stake increase comes ahead of AACR presentation of preclinical data on SLS009, Sellas’ CDK9 inhibitor targeting acute myeloid leukemia (AML).</li><li>Investor focus remains centered on the Phase 3 Regal trial of GPS, with 72 of 80 required survival events recorded as of Dec. 26, moving the study closer to topline analysis.</li></ul>Shares of Sellas Life Sciences Group, Inc. (SLS) jumped 5% in premarket trading on Monday after U.S. investment manager Dagco increased its stake by 78% ahead of a major AACR leukemia data catalyst and the closely watched Regal survival trigger.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> snapped four sessions of gains on Monday to end over 4% lower at $4.99.<h2 class="st-heading-2">Dagco Loads Up Ahead Of SLS009 AACR Data</h2>Data compiled by Quiver Quantitative showed that Dagco added 451,240 shares on Tuesday, bringing its total holdings to 1.03 million shares valued at $4.35 million as of March 31. The position now represents its second biggest holding at 1.01% of Dagco’s disclosed portfolio, placing Sellas among its healthcare bets alongside larger pharma holdings such as Merck, Thermo Fisher Scientific and Johnson &amp; Johnson.The stake increase comes just as Sellas prepares to present new preclinical findings on SLS009, its CDK9 inhibitor for acute myeloid leukemia (AML), during a poster session at AACR in San Diego on Tuesday.According to the company, lab studies showed that SLS009 triggered leukemia-cell death by increasing activity of caspase-3, a protein involved in the body’s natural cell-death process, while lowering survival signals such as MCL-1 and survivin that help cancer cells persist. The drug also showed stronger potency with repeated exposure, with early biological effects appearing within hours and becoming more pronounced over 24 hours.Notably, SLS009 remained active in AML carrying ASXL1 and TP53 mutations, which are genetic subtypes associated with treatment resistance and poorer outcomes.&nbsp;<h2 class="st-heading-2">Regal Survival Countdown In Focus</h2>While the AACR presentation represents a near-term catalyst, investor attention remains firmly centered on the company’s ongoing Phase 3 Regal trial evaluating GPS, an immunotherapy targeting the Wilms Tumor-1 antigen, as a maintenance treatment for AML patients whose disease returned but later entered remission after additional therapy.The event-driven study will begin final analysis once 80 overall-survival events are recorded. Sellas previously said 72 events had been logged as of Dec. 26, bringing the trial closer to the threshold required to initiate topline analysis.CEO Angelos Stergiou previously said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than expected compared with historical assumptions. Once the 80th event occurs, the company plans to proceed with database lock, statistical analysis, trial unblinding and disclosure of topline results.<h2 class="st-heading-2">How Do Retail Traders Feel About SLS?</h2>On Stocktwits, retail sentiment for SLS was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_png_226ba9d4c9.webp" alt="sls ss.png" width="973" height="147"><figcaption>SLS sentiment and message volume as of April 21 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/yG19/message/650823713">noted</a> Diagco’s stake and said, “It's likely clearly see the asymmetric upside with the margin of safety of no REGAL downside.”<stembedurl>https://stocktwits.com/yG19/message/650823713</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/vlucky16/message/650846855">said</a>, “Can't wait to get update on 009, since GPS has been put on hold for an 80th event that might happen from old age.”<stembedurl>https://stocktwits.com/vlucky16/message/650846855</stembedurl>SLS stock has surged over 280% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-premarket-ross-gerber-brand-backlash-ai-pivot-earnings-check/cZBIOqKRICO">Tesla Stock Rises Premarket: Investor Ross Gerber Says ‘People Just Hate The Brand Now’ As AI Pivot Faces Earnings Reality Check</a>

SLS Stock Jumps Premarket: US Investor Dagco Boosts Stake By 78% Ahead Of Fresh Cancer Drug Data Reveal 

Sellas is now Dagco’s second-largest disclosed holding, putting the small-cap leukemia biotech alongside pharma giants like Merck and Johnson & Johnson.

Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet

The mean of analysts' price targets for SELLAS Life Sciences Group, Inc. (SLS) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

While SLS stock has surged nearly 300% over the past year, ATNM has climbed 7% over the same period. (Photo credit: Getty Images)

SLS Vs ATNM: Which Cancer Stock Has Bigger Upside Ahead Of Fresh Data Reveal?

Analyst estimates suggest ATNM carries the wider valuation runway, with 342% upside versus about 66% for SLS.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Continue higher

Sideways action

Retreat lower

What’s your read on the market for next week?

Stocktwits

Stocktwits Polls

Investors are closely monitoring the trial's 80th event milestone as the primary catalyst for an unblinding and potential company buyout.

Intense debate is ongoing among shareholders regarding a contentious vote on issuing 20 million shares for executive compensation packages.

Retail investors and technical traders are frustrated by consistent market maker pinning that prevents a sustained breakout above the 5 dollar level.

A core group of long-term holders believe the upcoming trial data will lead to a multi-billion dollar acquisition by big pharma.

Current Price	$4.93
Prev Close	$4.95
Open	$4.95
Dividend Yield	0.00%
50-Day Moving Average	$4.91
Beta	0.83
Avg. Volume	4.58M
PE Ratio	-20.05

52-Week High	$6.14
52-Week Low	$1.36
Market Capitalization	$888.93M
EPS (Annual)	-$0.2463
Price to Book	10.65
Revenue Per Employee	$0.00

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc